Clinical Trial: Efficacy and Safety of QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma: a Phase II Clinical Study

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06939855) titled 'Efficacy and Safety of QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma: a Phase II Clinical Study' on April 15.

Brief Summary: This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: Bone and Soft Tissue Tumors

Intervention: DRUG: QL1706...